Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.35 | N/A | +23.25% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.35 | N/A | +23.25% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions impacting growth. They reaffirmed their commitment to advancing their product pipeline.
Management highlighted ongoing challenges in the market.
They emphasized the need for continued focus on product development.
The team remains committed to long-term goals despite current setbacks.
Day One Biopharma reported a narrower-than-expected loss per share, which was a positive surprise. However, the stock fell by 6.55% likely due to the lack of revenue information and no guidance provided for future performance. Investors may be concerned about the company's ability to navigate current market challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PALANTIR TECHNOLOGIE Class A
May 5, 2025